Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Xenetic Biosciences, Inc. (XBIO) had Consolidated Net Income/Loss of $-2.68M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$2.98M |
|
$-2.68M |
|
-- |
|
$2.98M |
|
$5.81M |
|
$-2.83M |
|
$0.15M |
|
$-2.68M |
|
$-2.68M |
|
$-2.68M |
|
$-2.68M |
|
|
Consolidated Net Income/Loss |
$-2.68M |
$-2.68M |
|
$-2.83M |
|
$-2.83M |
|
1.70M |
|
1.70M |
|
$-1.58 |
|
$-1.58 |
|
| Balance Sheet Financials | |
$8.05M |
|
-- |
|
$0.31M |
|
$8.36M |
|
$0.97M |
|
-- |
|
-- |
|
$0.97M |
|
$7.39M |
|
$7.40M |
|
$7.40M |
|
2.29M |
|
| Cash Flow Statement Financials | |
$-2.29M |
|
-- |
|
$4.00M |
|
$6.17M |
|
$7.88M |
|
$1.72M |
|
$0.06M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.32 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-95.23% |
|
-95.23% |
|
-95.23% |
|
-90.07% |
|
-90.07% |
|
$-2.29M |
|
-- |
|
-- |
|
-- |
|
0.36 |
|
-- |
|
-- |
|
-- |
|
-36.26% |
|
-36.25% |
|
-32.05% |
|
-36.25% |
|
$3.23 |
|
$-1.34 |
|
$-1.34 |
|